Early phase clinical trials to identify optimal dosing and safety

Molecular Oncology

Volumn 9, Issue 5, 2015, Pages 997-1007

  Cook, Natalie ^a,b   Hansen, Aaron R ^a,b   Siu, Lillian L ^a,b   Abdul Razak, Albiruni R ^a,b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Phase I trials; Recommended phase 2 dose; Toxicity

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; DOSE RESPONSE; DRUG SAFETY; HUMAN; MOLECULARLY TARGETED THERAPY; NONHUMAN; OPTIMAL DRUG DOSE; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; TOXICITY TESTING; CLINICAL TRIAL (TOPIC); NEOPLASMS;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASMS;

EID: 84928549216     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2014.07.025     Document Type: Review

References (66)

1. Agoram B.M. Use of pharmacokinetic/pharmacodynamic modelling for starting dose selection in first-in-human trials of high-risk biologics. Br. J. Clin. Pharmacol. 2009, 67:153-160.
2. Agrawal N., Frederick M.J., Pickering C.R., Bettegowda C., Chang K., Li R.J., Fakhry C., Xie T.X., Zhang J., Wang J., Zhang N., El-Naggar A.K., Jasser S.A., Weinstein J.N., Trevino L., Drummond J.A., Muzny D.M., Wu Y., Wood L.D., Hruban R.H., Westra W.H., Koch W.M., Califano J.A., Gibbs R.A., Sidransky D., Vogelstein B., Velculescu V.E., Papadopoulos N., Wheeler D.A., Kinzler K.W., Myers J.N. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 2011, 333:1154-1157.
3. Arnheiter H., Frese M., Kambadur R., Meier E., Haller O. Mx transgenic mice-animal models of health. Curr. Top. Microbiol. Immunol. 1996, 206:119-147.
4. Babb J., Rogatko A., Zacks S. Cancer phase I clinical trials: efficient dose escalation with overdose control. Stat. Med. 1998, 17:1103-1120.
5. Bedard P.L., Hansen A.R., Ratain M.J., Siu L.L. Tumour heterogeneity in the clinic. Nature 2013, 501:355-364.
6. Begley C.G., Ellis L.M. Drug development: raise standards for preclinical cancer research. Nature 2012, 483:531-533.
7. Belum V.R., Fischer A., Choi J.N., Lacouture M.E. Dermatological adverse events from BRAF inhibitors: a growing problem. Curr. Oncol. Rep. 2013, 15:249-259.
8. Campbell P.J., Yachida S., Mudie L.J., Stephens P.J., Pleasance E.D., Stebbings L.A., Morsberger L.A., Latimer C., McLaren S., Lin M.L., McBride D.J., Varela I., Nik-Zainal S.A., Leroy C., Jia M., Menzies A., Butler A.P., Teague J.W., Griffin C.A., Burton J., Swerdlow H., Quail M.A., Stratton M.R., Iacobuzio-Donahue C., Futreal P.A. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 2010, 467:1109-1113.
9. Chen Z., Cheng K., Walton Z., Wang Y., Ebi H., Shimamura T., Liu Y., Tupper T., Ouyang J., Li J., Gao P., Woo M.S., Xu C., Yanagita M., Altabef A., Wang S., Lee C., Nakada Y., Pena C.G., Sun Y., Franchetti Y., Yao C., Saur A., Cameron M.D., Nishino M., Hayes D.N., Wilkerson M.D., Roberts P.J., Lee C.B., Bardeesy N., Butaney M., Chirieac L.R., Costa D.B., Jackman D., Sharpless N.E., Castrillon D.H., Demetri G.D., Janne P.A., Pandolfi P.P., Cantley L.C., Kung A.L., Engelman J.A., Wong K.K. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature 2012, 483:613-617.
10. Cheung Y.K., Chappell R. Sequential designs for phase I clinical trials with late-onset toxicities. Biometrics 2000, 56:1177-1182.
11. Chiu C.W., Nozawa H., Hanahan D. Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesis. J.Clin. Oncol.: Official J. Am. Soc. Clin. Oncol. 2010, 28:4425-4433.
12. Clohessy J.G., de Stanchina E. Infrastructure needs for translational integration of mouse and human trials. Cold Spring Harbor Protoc. 2013, 2013.
13. Committee for Medicinal Products for Human use (CHMP) Guideline on Strategies to Identify and Mitigate Risks for First-in-human Clinical Trials with Investigational Medicinal Products 2007.
14. Corsello S.M., Barnabei A., Marchetti P., De Vecchis L., Salvatori R., Torino F. Endocrine side effects induced by immune checkpoint inhibitors. J.Clin. Endocrinol. Metab. 2013, 98:1361-1375.
15. DeMichele A., Berry D.A., Zujewski J., Hunsberger S., Rubinstein L., Tomaszewski J.E., Kelloff G., Perlmutter J., Buxton M., Lyandres J., Albain K.S., Benz C., Jo Chien A., Haluska P., Leyland-Jones B., Liu M.C., Munster P., Olopade O., Park J.W., Parker B.A., Pusztai L., Tripathy D., Rugo H., Yee D., Esserman L. Developing safety criteria for introducing new agents into neoadjuvant trials. Clin. Cancer Res. 2013, 19:2817-2823.
16. Desai S.P., Ben-Josef E., Normolle D.P., Francis I.R., Greenson J.K., Simeone D.M., Chang A.E., Colletti L.M., Lawrence T.S., Zalupski M.M. Phase I study of oxaliplatin, full-dose gemcitabine, and concurrent radiation therapy in pancreatic cancer. J.Clin. Oncol. 2007, 25:4587-4592.
17. Dienstmann R., Serpico D., Rodon J., Saura C., Macarulla T., Elez E., Alsina M., Capdevila J., Perez-Garcia J., Sanchez-Olle G., Aura C., Prudkin L., Landolfi S., Hernandez-Losa J., Vivancos A., Tabernero J. Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials. Mol. Cancer Ther. 2012, 11:2062-2071.
18. Doussau A., Thiébaut R., Paoletti X. Dose-finding design using mixed-effect proportional odds model for longitudinal graded toxicity data in phase I oncology clinical trials. Stat. Med. 2013, 32:5430-5447.
19. Dowlati A. Controversies in multi-institutional phase I clinical trials. Clin. Adv. Hematol. Oncol.: H&O 2009, 7:518-520.
20. Druker B.J., Talpaz M., Resta D.J., Peng B., Buchdunger E., Ford J.M., Lydon N.B., Kantarjian H., Capdeville R., Ohno-Jones S., Sawyers C.L. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N.Engl. J. Med. 2001, 344:1031-1037.
21. Flaherty K.T., Puzanov I., Kim K.B., Ribas A., McArthur G.A., Sosman J.A., O'Dwyer P.J., Lee R.J., Grippo J.F., Nolop K., Chapman P.B. Inhibition of mutated, activated BRAF in metastatic melanoma. N.Engl. J. Med. 2010, 363:809-819.
22. Fontes Jardim D.L., Hess K.R., LoRusso P.M., Kurzrock R., Hong D.S. Predictive value of phase I trials for safety in later trials and final approved dose: analysis of 61 approved cancer drugs. Clin. Cancer Res. 2014, 20(2):281-288.
23. Food and Drug Administration, H.H.S International conference on harmonisation; guidance on S9 nonclincal evaluation for anticancer pharmaceuticals; availability. Notice. Federal Register 2010, 75:10487-10488.
24. Frese K.K., Tuveson D.A. Maximizing mouse cancer models. Nat. Rev. Cancer 2007, 7:645-658.
25. Gerlinger M., Rowan A.J., Horswell S., Larkin J., Endesfelder D., Gronroos E., Martinez P., Matthews N., Stewart A., Tarpey P., Varela I., Phillimore B., Begum S., McDonald N.Q., Butler A., Jones D., Raine K., Latimer C., Santos C.R., Nohadani M., Eklund A.C., Spencer-Dene B., Clark G., Pickering L., Stamp G., Gore M., Szallasi Z., Downward J., Futreal P.A., Swanton C. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N.Engl. J. Med. 2012, 366:883-892.
26. Goodman S.N., Zahurak M.L., Piantadosi S. Some practical improvements in the continual reassessment method for phase I studies. Stat. Med. 1995, 14:1149-1161.
27. Gutmann D.H., Hunter-Schaedle K., Shannon K.M. Harnessing preclinical mouse models to inform human clinical cancer trials. J.Clin. Invest. 2006, 116:847-852.
28. Haibe-Kains B., El-Hachem N., Birkbak N.J., Jin A.C., Beck A.H., Aerts H.J., Quackenbush J. Inconsistency in large pharmacogenomic studies. Nature 2013, 504:389-393.
29. Hidalgo M., Bruckheimer E., Rajeshkumar N.V., Garrido-Laguna I., De Oliveira E., Rubio-Viqueira B., Strawn S., Wick M.J., Martell J., Sidransky D. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol. Cancer Ther. 2011, 10:1311-1316.
30. Hutchinson L., Kirk R. High drug attrition rates-where are we going wrong? Nature reviews. Clin. Oncol. 2011, 8:189-190.
31. Jain R.K., Lee J.J., Hong D., Markman M., Gong J., Naing A., Wheler J., Kurzrock R. Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse. Clin. Cancer Res. 2010, 16:1289-1297.
32. James P., Bebee P., Beekman L., Browning D., Innes M., Kain J., Royce-Westcott T., Waldinger M. Effort tracking metrics provide data for optimal budgeting and workload management in therapeutic cancer clinical trials. J.Natl. Compr. Cancer Netw.: JNCCN 2011, 9:1343-1352.
33. Johnson J.I., Decker S., Zaharevitz D., Rubinstein L.V., Venditti J.M., Schepartz S., Kalyandrug S., Christian M., Arbuck S., Hollingshead M., Sausville E.A. Relationships between drug activity in NCI preclinical invitro and invivo models and early clinical trials. Br. J. Cancer 2001, 84:1424-1431.
34. Jones S., Zhang X., Parsons D.W., Lin J.C., Leary R.J., Angenendt P., Mankoo P., Carter H., Kamiyama H., Jimeno A., Hong S.M., Fu B., Lin M.T., Calhoun E.S., Kamiyama M., Walter K., Nikolskaya T., Nikolsky Y., Hartigan J., Smith D.R., Hidalgo M., Leach S.D., Klein A.P., Jaffee E.M., Goggins M., Maitra A., Iacobuzio-Donahue C., Eshleman J.R., Kern S.E., Hruban R.H., Karchin R., Papadopoulos N., Parmigiani G., Vogelstein B., Velculescu V.E., Kinzler K.W. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008, 321:1801-1806.
35. Le Tourneau C., Gan H.K., Razak A.R., Paoletti X. Efficiency of new dose escalation designs in dose-finding phase I trials of molecularly targeted agents. PLoS One 2012, 7:e51039.
36. Le Tourneau C., Lee J.J., Siu L.L. Dose escalation methods in phase I cancer clinical trials. J.Natl. Cancer Inst. 2009, 101:708-720.
37. Le Tourneau C., Stathis A., Vidal L., Moore M.J., Siu L.L. Choice of starting dose for molecularly targeted agents evaluated in first-in-human phase I cancer clinical trials. J.Clin. Oncol. 2010, 28:1401-1407.
38. LoRusso P.M., Boerner S.A., Seymour L. An overview of the optimal planning, design, and conduct of phase I studies of new therapeutics. Clin. Cancer Res. 2010, 16:1710-1718.
39. Manji A., Brana I., Amir E., Tomlinson G., Tannock I.F., Bedard P.L., Oza A., Siu L.L., Abdul Razak A.R. Evolution of clinical trial design in early drug development: systematic review of expansion cohort use in single-agent phase I cancer trials. J.Clin. Oncol. 2013, 31(33):4260-4267.
40. Morelli M.P., Calvo E., Ordonez E., Wick M.J., Viqueira B.R., Lopez-Casas P.P., Bruckheimer E., Calles-Blanco A., Sidransky D., Hidalgo M. Prioritizing phase I treatment options through preclinical testing on personalized tumorgraft. J.Clin. Oncol.: Official J. Am. Soc. Clin. Oncol. 2012, 30:e45-48.
41. Muler J.H., McGinn C.J., Normolle D., Lawrence T., Brown D., Hejna G., Zalupski M.M. Phase I trial using a time-to-event continual reassessment strategy for dose escalation of cisplatin combined with gemcitabine and radiation therapy in pancreatic cancer. J.Clin. Oncol. 2004, 22:238-243.
42. Normolle D., Lawrence T. Designing dose-escalation trials with late-onset toxicities using the time-to-event continual reassessment method. J.Clin. Oncol. 2006, 24:4426-4433.
43. O'Quigley J., Pepe M., Fisher L. Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics 1990, 33-48.
44. Ocana A., Pandiella A., Siu L.L., Tannock I.F. Preclinical development of molecular-targeted agents for cancer. Nature reviews. Clin. Oncol. 2011, 8:200-209.
45. Parsons D.W., Jones S., Zhang X., Lin J.C., Leary R.J., Angenendt P., Mankoo P., Carter H., Siu I.M., Gallia G.L., Olivi A., McLendon R., Rasheed B.A., Keir S., Nikolskaya T., Nikolsky Y., Busam D.A., Tekleab H., Diaz L.A., Hartigan J., Smith D.R., Strausberg R.L., Marie S.K., Shinjo S.M., Yan H., Riggins G.J., Bigner D.D., Karchin R., Papadopoulos N., Parmigiani G., Vogelstein B., Velculescu V.E., Kinzler K.W. An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321:1807-1812.
46. Parulekar W.R., Eisenhauer E.A. Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice. J.Natl. Cancer Inst. 2004, 96:990-997.
47. Postel-Vinay S., Gomez-Roca C., Molife L.R., Anghan B., Levy A., Judson I., De Bono J., Soria J.-C., Kaye S., Paoletti X. Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities?. J.Clin. Oncol. 2011, 29:1728-1735.
48. Reiner E., Paoletti X., O'Quigley J. Operating characteristics of the standard phase I clinical trial design. Comput. Stat. Data Anal. 1999, 30:303-315.
49. Renouf D.J., Velazquez-Martin J.P., Simpson R., Siu L.L., Bedard P.L. Ocular toxicity of targeted therapies. J.Clin. Oncol.: Official J. Am. Soc. Clin. Oncol. 2012, 30:3277-3286.
50. Roche K., Paul N., Smuck B., Whitehead M., Zee B., Pater J., Hiatt M.A., Walker H. Factors affecting workload of cancer clinical trials: results of a multicenter study of the national cancer institute of Canada clinical trials group. J.Clin. Oncol.: Official J. Am. Soc. Clin. Oncol. 2002, 20:545-556.
51. Rogatko A., Schoeneck D., Jonas W., Tighiouart M., Khuri F.R., Porter A. Translation of innovative designs into phase I trials. J.Clin. Oncol. 2007, 25:4982-4986.
52. Shah S.P., Roth A., Goya R., Oloumi A., Ha G., Zhao Y., Turashvili G., Ding J., Tse K., Haffari G., Bashashati A., Prentice L.M., Khattra J., Burleigh A., Yap D., Bernard V., McPherson A., Shumansky K., Crisan A., Giuliany R., Heravi-Moussavi A., Rosner J., Lai D., Birol I., Varhol R., Tam A., Dhalla N., Zeng T., Ma K., Chan S.K., Griffith M., Moradian A., Cheng S.W., Morin G.B., Watson P., Gelmon K., Chia S., Chin S.F., Curtis C., Rueda O.M., Pharoah P.D., Damaraju S., Mackey J., Hoon K., Harkins T., Tadigotla V., Sigaroudinia M., Gascard P., Tlsty T., Costello J.F., Meyer I.M., Eaves C.J., Wasserman W.W., Jones S., Huntsman D., Hirst M., Caldas C., Marra M.A., Aparicio S. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012, 486:395-399.
53. Sikder H., Huso D.L., Zhang H., Wang B., Ryu B., Hwang S.T., Powell J.D., Alani R.M. Disruption of Id1 reveals major differences in angiogenesis between transplanted and autochthonous tumors. Cancer Cell 2003, 4:291-299.
54. Simon R., Rubinstein L., Arbuck S.G., Christian M.C., Freidlin B., Collins J. Accelerated titration designs for phase I clinical trials in oncology. J.Natl. Cancer Inst. 1997, 89:1138-1147.
55. Sleijfer S., Wiemer E. Dose selection in phase I studies: why we should always go for the top. J.Clin. Oncol.: Official J. Am. Soc. Clin. Oncol. 2008, 26:1576-1578.
56. Sophie Postel-Vinay E.R., Le Tourneau Christophe, Olmos David, Massard Christophe, Ivy Percy, Seymour Lesley, Siu Lillian L., Lacombe Denis, Paoletti Xavier, Kaye Stan B., Verweij Jaap, Collette Laurence, Soria Jean-Charles Towards New Methods for the Determination of Dose Limiting Toxicities and Recommended Dose of Molecularly Targeted Agents 2013, European Cancer Congress (ECCO-ESMO-ESTRO), Amsterdam.
57. Storer B.E. Design and analysis of phase I clinical trials. Biometrics 1989, 925-937.
58. Tentler J.J., Tan A.C., Weekes C.D., Jimeno A., Leong S., Pitts T.M., Arcaroli J.J., Messersmith W.A., Eckhardt S.G. Patient-derived tumour xenografts as models for oncology drug development. Nat. Rev. Clin. Oncol. 2012, 9:338-350.
59. Tevaarwerk A., Wilding G., Eickhoff J., Chappell R., Sidor C., Arnott J., Bailey H., Schelman W., Liu G. Phase I study of continuous MKC-1 in patients with advanced or metastatic solid malignancies using the modified time-to-event continual reassessment method (TITE-CRM) dose escalation design. Invest. New Drugs 2012, 30:1039-1045.
60. Tomaszewski J.E. Multi-species toxicology approaches for oncology drugs: the US perspective. Eur. J. Cancer 2004, 40:907-913.
61. Tsimberidou A.M., Iskander N.G., Hong D.S., Wheler J.J., Falchook G.S., Fu S., Piha-Paul S., Naing A., Janku F., Luthra R., Ye Y., Wen S., Berry D., Kurzrock R. Personalized medicine in a phase I clinical trials program: the MD Anderson cancer center initiative. Clin. Cancer Res.: J. Am. Assoc. Cancer Res. 2012, 18:6373-6383.
62. Uren S.C., Kirkman M.B., Dalton B.S., Zalcberg J.R. Reducing clinical trial monitoring resource allocation and costs through remote access to electronic medical records. J.Oncol. Prac./Am. Soc. Clin. Oncol. 2013, 9:e13-16.
63. Von Hoff D.D., Stephenson J.J., Rosen P., Loesch D.M., Borad M.J., Anthony S., Jameson G., Brown S., Cantafio N., Richards D.A., Fitch T.R., Wasserman E., Fernandez C., Green S., Sutherland W., Bittner M., Alarcon A., Mallery D., Penny R. Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J.Clin. Oncol.: Official J. Am. Soc. Clin. Oncol. 2010, 28:4877-4883.
64. Walter M.J., Shen D., Ding L., Shao J., Koboldt D.C., Chen K., Larson D.E., McLellan M.D., Dooling D., Abbott R., Fulton R., Magrini V., Schmidt H., Kalicki-Veizer J., O'Laughlin M., Fan X., Grillot M., Witowski S., Heath S., Frater J.L., Eades W., Tomasson M., Westervelt P., DiPersio J.F., Link D.C., Mardis E.R., Ley T.J., Wilson R.K., Graubert T.A. Clonal architecture of secondary acute myeloid leukemia. N.Engl. J. Med. 2012, 366:1090-1098.
65. Yao J.C., Shah M.H., Ito T., Bohas C.L., Wolin E.M., Van Cutsem E., Hobday T.J., Okusaka T., Capdevila J., de Vries E.G., Tomassetti P., Pavel M.E., Hoosen S., Haas T., Lincy J., Lebwohl D., Oberg K. Everolimus for advanced pancreatic neuroendocrine tumors. N.Engl. J. Med. 2011, 364:514-523. Rad001 in Advanced Neuroendocrine Tumors, T.T.S.G.
66. Yin G., Zheng S., Xu J. Fractional dose-finding methods with late-onset toxicity in phase I clinical trials. J.Biopharm. Stat. 2013, 23:856-870.